Business
Mezzion Secures $20 Million in Strategic Funding to Advance Global Phase 3 Clinical Development of Udenafil for Fontan Patients
Mezzion Pharma Co., Ltd. (Mezzion) announced a major milestone in their clinical development program, having secured approximately $20 million USD in strategic funding to support the ongoing global Phase 3 FUEL-2 trial of udenafil for patients with Fontan circulation.
About this update from Mezzion Pharma Co., Ltd.
[{"type":"text","content":"SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Mezzion Pharma Co., Ltd. (Mezzion) announced a major milestone in their clinical development program, having secured approximately $20 million USD in strategic funding to support the ongoing global Phase 3 FUEL-2 trial of udenafil for patients with Fontan circulation.","length":318,"tagName":"p"},{"type":"image","alt":"Mezzion Logo for print (PRNewsfoto/Mezzion Pharmaceuticals, Inc)","displaySize":"","headline":null,"caption":"Mezzion Logo for print (PRNewsfoto/Mezzion Pharmaceuticals, Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":78,"url":"https://media.zenfs.com/en/prnewswire.com/439f08b9a932e7323408a39cbbc3eda2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZFRV5N791gx1lxR7uiFj7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/439f08b9a932e7323408a39cbbc3eda2","width":400,"height":78}},"href":"https://mma.prnewswire.com/media/2666464/Mezzion_Pharmaceuticals__Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The financing was led by Midas-Meritz New Technology Finance Association and KDBC-Korea Investment & Securities New Technology Investment Association, representing a strong vote of confidence from top-tier institutional investors in Mezzion's late-stage pipeline and long-term growth strategy.","length":301,"tagName":"p"},{"type":"text","content":""We are pleased to partner with Midas Private Equity (Midas PE) and KDBC as we enter a critical phase in the development of udenafil for the Fontan population, a community with significant unmet medical need," said Dean Park, Chairman and CEO of Mezzion. "This investment affirms the strength of our data, the quality of our science, and the potential impact of our work on patients worldwide."","length":414,"tagName":"p"},{"type":"text","content":"Midas PE, the lead investor, is a prominent private equity firm with over $230 million in assets under management. CEO Lim Chun-soo expressed strong confidence in Mezzion's direction:","length":187,"tagName":"p"},{"type":"text","content":""After a detailed review of Mezzion's FUEL-1 results and the ongoing FUEL-2 protocol, we believe udenafil is well positioned for successful global Phase 3 completion and regulatory approval. We ar...